Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus (nirsevimab), a preventative therapy for Respiratory Syncytial Virus (RSV), in China. Nirsevimab, a long-acting monoclonal antibody (mAb), is the first and only RSV preventative therapy in China that covers a wide range of infants, including healthy full-term infants, premature infants, and those susceptible to severe RSV infection due to special health conditions.
In March 2017, AstraZeneca (AZ) agreed to take over the development and preliminary regulatory filing rights for the drug, with Sanofi leading the commercialization efforts. Beyfortus has received approvals in the European Union and the United States in October 2022 and July 2023, respectively, and is awaiting regulatory decisions in Japan and other markets. The drug was approved to prevent lower respiratory tract infections caused by RSV in newborns and infants in China in December 2023.- Flcube.com
